TPD is a disease and target agnostic modalityKymera is committed to demonstrate its impact across several diseases. IRAK4 degradation fulfills Kymera’s Drug Development Principles. Validated pathway in several immune-inflammatory diseases with key undrugged or not well drugged node. IRAK4 degradation superior to inhibition. In blocking secretion of cytokines as well as in intracellular signaling.

Join for free to read